Three companies in BioBAY bring good news
Aworld-leading biomedical ecosystem has taken shape in BioBAY, and theenterprises in it are developing fast. Last month, three companies in BioBAY broughtgood news.SABiotech (Suzhou) Pte Ltd, a wholly-owned subsidiary of Advaccine Biotech(Suzhou) Co Ltd, an innovative vaccine developer, received the permit formanufacturing “biological products for prevention”, becoming the first biopharmaceuticalcompany in Suzhou to get the permit.Inthe same month, SuzhouIndustrial Park Biotech Development Co Ltd, operator of BioBAY, and itspartners launched the country’s first biomedicine cluster-based REI... [MORE]
   
Excellent business services back robust growth of biomedical industry
SIP gives top priority to the development of biomedical industry. SIP’s biomedical industry has maintained an annual growth of more than 20% for many years, and the total industrial output value exceeded RMB100 billion last year. For this achievement, SIP’s excellent business services play an important role. BioBAY serves as the “main front” for the development of the biomedicalindustry in SIP. Compared with other industrial clusters of similar kind, itfocuses more on attracting teams and startups engaged in high and newbiological technology. “Ten years ago, our investment promotion staff... [MORE]
   
14 biotech companies settle down in new zone of BioBAY
Zone A, part of the Phase III project of BioBAY, came intooperation on May 27. A total of 14 enterprises have settled down in it.Located at Sangtian Island, the Phase III project consists ofZone A and Zone B, with a total area of 10.19 hectares. Zone A, with a landarea of about 7.08 hectares and a total floor area of 133,000 square meters,serves as an industrialization base for high-end medical devices and new drugs.Zone B is scheduled to complete at the end of this year.Among the new settlers are a number of enterprises engaged indeveloping and manufacturing innovative drugs and therapies for... [MORE]